MOVIVA® launch spotlight at ESGE Days 2026

“Turn down the food noise”

During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA^®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA^® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium.

Tübingen, 7 May 2026. “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA^®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.” Marcus Felstead, Chief Commercial Officer of Erbe.

Targeting hunger at its source

For many people living with obesity, persistent hunger signals and cravings make long-term weight management difficult. The upper part of the stomach - the fundus - is one of the main sites where ghrelin is produced, a hormone that triggers hunger. Gastric mucosal ablation targets this area, reduces production of ghrelin and therefore patients experience less cravings.

MOVIVA^® is an advanced hybrid instrument designed for GMA.  It combines two key functions in one product. Injection of a submucosal fluid cushion that protects deeper tissue layers from thermal injury and superficial thermal ablation of the mucosa using argon plasma coagulation (APC). MOVIVA^® is powered by the moveAPD mode, ensuring broad and consistent ablation.

Figure 1 How GMA with MOVIVA^® works

Early clinical experience with GMA

Clinical evidence indicates that fundal GMA using MOVIVA^® induces weight loss. GMA alone achieves 7.7% total body weight loss (TBWL) after 6 months in early studies.

GMA may be used either on its own or in combination with endoscopic sleeve gastroplasty (ESG). When combined, early data indicate further improvements, with up to 24% TBWL reported after 12 months – approaching outcomes seen with surgical sleeve gastrectomy, while remaining far less invasive. To date, more than 150 patients have been treated with MOVIVA^®, adding to the growing clinical experience with this approach.

Symposium at ESGE Days

At ESGE Days 2026, Erbe will host a symposium with Prof. Aayed Alqahtani, Saudi Arabia, Prof. Ivo Boskoski, Prof. Roberta Maselli, both Italy, and Prof. Bu´Hussain Hayee, UK, titled: “A Novel Endoscopic Therapy for Obesity: Early Clinical Experience with Gastric Mucosal Ablation (GMA) in the fundus.”

The session will provide insights into the early clinical experience with GMA and create a platform for discussing the potential role of this emerging endoscopic therapy in obesity treatment. To stay up to date physicians can also visit the MOVIVA^® website.

MOVIVA^® is currently available in CE and CE-related markets.

Downlad the press release here